drugset / Trial / NCT05092841
A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled and multicenter 3 phase trial evaluating the therapeutic effect and safety of CMT1A by PXT3003. This double-blind study will assess in parallel groups 1 dose of PXT3003 compared to Placebo in CMT1A patients treated for 15 months.
Timeline
- Start
- 2021-09-28
- Primary completion
- 2024-03-18
- Completion
- 2024-03-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baclofen | Small molecule | — | Oral |
| Subject | Naltrexone | Small molecule | — | Oral |
| Subject | Sorbitol | Small molecule | — | Oral |